Frontier Medicines utilizes a proprietary chemoproteomics platform combined with covalent chemistry and machine learning to identify and develop small-molecule therapies targeting previously undruggable disease-causing proteins. This approach enables the creation of precision medicines tailored to genetically-defined patient populations, enhancing treatment efficacy and patient outcomes.
Funding
$255.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-causing proteins are considered "undruggable" due to their structural properties or lack of suitable binding sites for traditional small-molecule drugs. This limitation hinders the development of effective therapies for genetically-defined patient populations.
Solution
Frontier Medicines is developing small-molecule therapies against these previously undruggable disease-causing proteins. The company's proprietary chemoproteomics platform, combined with covalent chemistry and machine learning, enables the identification of novel binding pockets and the design of precision medicines. This approach aims to create targeted treatments for genetically-defined patient populations, maximizing therapeutic efficacy and improving patient outcomes. The Frontier™ Platform integrates cutting-edge technologies such as machine learning, context-dependent screening, and biophysical and analytical methods.
Target Audience
The primary target audience includes patients with genetically-defined diseases and the clinicians who treat them.
Features
- Chemoproteomics platform for identifying novel drug targets and binding sites
- Covalent chemistry techniques for designing molecules that form irreversible bonds with target proteins
- Machine learning algorithms for predicting drug-target interactions and optimizing drug design
- Context-dependent screening to identify compounds with selective activity in disease-relevant cellular environments
- Development of precision medicines tailored to genetically-defined patient populations
- Focus on unlocking the proteome to small-molecule interventions against otherwise undruggable disease-causing targets